Hennepin Healthcare suspends clinical trial of ketamine

Hennepin Healthcare suspends clinical trial of ketamine

MINNEAPOLIS (KMSP) – A controversy following allegations that Hennepin Healthcare enrolled patients in a clinical trial of the powerful sedative Ketamine without their knowledge has forced the hospital to suspend the program and review its procedures, officials said. The study began last August with a goal of determining which of the drugs already in use were most […]

Watchman FLX in Clinical Trial at MedStar Heart and Vascular Institute

Watchman FLX in Clinical Trial at MedStar Heart and Vascular Institute

June 26, 2018 — MedStar Heart & Vascular Institute physicians participating in a clinical trial have become the first in the Mid-Atlantic region to implant the Watchman FLX device. The Watchman FLX is the next generation of a potentially life-changing device proven to reduce the risk of stroke in certain patients with atrial fibrillation (AFib). […]

Unreported clinical trial of the week: Pyridoxine/doxylamine for nausea and vomiting of pregnancy in pregnant …

Unreported clinical trial of the week: Pyridoxine/doxylamine for nausea and vomiting of pregnancy in pregnant …

Nick DeVito, Navindra Persaud, Ben Goldacre Background The US FDA Amendments Act (FDAAA 2007) requires certain clinical trials to report their results onto ClinicalTrials.gov within one year of completion. Our FDAAA TrialsTracker shows all individual trials that breach this legal requirement. Once a week, we write about one unreported clinical trial: you can read more background here. Trial NCT02045901 This […]

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in …

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in …

Paris (France) and Mechelen (Belgium), 26 June 2018, 22.01 CET – Servier, an independent international pharmaceutical company, and Galapagos NV (Euronext & NASDAQ: GLPG) announce the start of a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis patients: ROCCELLA. Galapagos will be eligible to receive a €9 million milestone payment upon first dosing of […]

Elligo Health Research and HealthiVibe Partner to Deliver Patient Insights

Elligo Health Research and HealthiVibe Partner to Deliver Patient Insights

AUSTIN, Texas & ARLINGTON, Va.–(BUSINESS WIRE)–Jun 26, 2018–Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, has partnered with HealthiVibe, an organization that gathers patient insights to optimize clinical trials. The goal of the partnership is to bring the patient to the center of the clinical trial […]

uMotif gets $3.2M for patient-first approach to clinical trial innovation

uMotif gets $3.2M for patient-first approach to clinical trial innovation

Patient-facing clinical trial software company uMotif has raised $3.2 million (£2.4 million) in a new funding round led by independent investment manager Albion Capital, with additional participation from unnamed angel investors. uMotif makes apps for capturing consent, electronic patient-reported outcomes (ePRO), and electronic clinical outcome assessment (eCOA). The UK-based company, founded in 2012, works with […]

Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients …

Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients …

WAYNE, Pa., June 26, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that the first patient has been dosed in Aclaris’ Phase 2 clinical trial of its JAK inhibitor product […]

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

“Our approach to drug discovery and development at Rigel is to identify molecules that modulate significant immune system processes, potentially allowing for wide-ranging application across different immune conditions or diseases impacted by the immune system,” said Raul Rodriguez, president and CEO of Rigel. “We are excited to explore the broad potential of R835 in autoimmune […]